Role of IP-10 to Predict Clinical Progression and Response to IL-6 Blockade With Sarilumab in Early COVID-19 Pneumonia. A Subanalysis of the SARICOR Clinical Trial

Background: The Clinical Trial of Sarilumab in Adults With COVID-19 (SARICOR) showed that patients with coronavirus disease 2019 (COVID-19) pneumonia and increased levels of interleukin (IL)-6 might benefit from blockade of the IL-6 pathway. However, the benefit from this intervention might not be uniform. In this subanalysis, we sought to determine if other immunoactivation markers, besides IL-6, could identify which subgroup of patients benefit most from this intervention.

Methods: The SARICOR trial was a phase II, open-label, multicenter, controlled trial (July 2020-March 2021) in which patients were randomized to receive usual care (UC; control group), UC plus a single dose of sarilumab 200 mg (sarilumab-200 group), or UC plus a single dose of sarilumab 400 mg (sarilumab-400 group). Patients who had baseline serum samples for cytokine determination (IL-8, IL-10, monocyte chemoattractant protein-1, interferon-inducible protein [IP]-10) were included in this secondary analysis. Progression to acute respiratory distress syndrome (ARDS) according to cytokine levels and treatment received was evaluated.

Results: One hundred one (88%) of 115 patients enrolled in the SARICOR trial had serum samples (control group: n = 33; sarilumab-200: n = 33; sarilumab-400: n = 35). Among all evaluated biomarkers, IP-10 showed the strongest association with treatment outcome. Patients with IP-10 ≥2500 pg/mL treated with sarilumab-400 had a lower probability of progression (13%) compared with the control group (58%; hazard ratio, 0.19; 95% CI, 0.04-0.90; = .04). Conversely, patients with IP-10 <2500 pg/mL did not show these differences.

Conclusions: IP-10 may predict progression to ARDS in patients with COVID-19 pneumonia and IL-6 levels >40 pg/mL. Importantly, IP-10 value <2500 pg/mL might discriminate those individuals who might not benefit from sarilumab therapy among those with high IL-6 levels.

Citing Articles

Dysregulated Inflammatory Cytokine Levels May Be Useful Markers in a Better Up-Dated Management of COVID-19.

Iuliano M, Mongiovi R, Parente A, Kertusha B, Carraro A, Marocco R Curr Issues Mol Biol. 2024; 46(8):8890-8902.

PMID: 39194742 PMC: 11352939. DOI: 10.3390/cimb46080525.

References

Jiang Y, Xu J, Zhou C, Wu Z, Zhong S, Liu J . Characterization of cytokine/chemokine profiles of severe acute respiratory syndrome. Am J Respir Crit Care Med. 2005; 171(8):850-7. DOI: 10.1164/rccm.200407-857OC. View

Coperchini F, Chiovato L, Rotondi M . Interleukin-6, CXCL10 and Infiltrating Macrophages in COVID-19-Related Cytokine Storm: Not One for All But All for One!. Front Immunol. 2021; 12:668507. PMC: 8107352. DOI: 10.3389/fimmu.2021.668507. View

Merchante N, Carcel S, Garrido-Gracia J, Trigo-Rodriguez M, Esteban Moreno M, Leon-Lopez R . Early Use of Sarilumab in Patients Hospitalized with COVID-19 Pneumonia and Features of Systemic Inflammation: the SARICOR Randomized Clinical Trial. Antimicrob Agents Chemother. 2021; 66(2):e0210721. PMC: 8846457. DOI: 10.1128/AAC.02107-21. View

Gallagher J, Morgan R . Successful immunomodulators for the treatment of COVID-19 have opened the pathway for comparative trials. Clin Microbiol Infect. 2022; 29(1):7-9. PMC: 9575309. DOI: 10.1016/j.cmi.2022.10.016. View

Leon Lopez R, Carcel Fernandez S, Limia Perez L, Romero Palacios A, Fernandez-Roldan M, Alonso E . Efficacy and safety of early treatment with sarilumab in hospitalised adults with COVID-19 presenting cytokine release syndrome (SARICOR STUDY): protocol of a phase II, open-label, randomised, multicentre, controlled clinical trial. BMJ Open. 2020; 10(11):e039951. PMC: 7668373. DOI: 10.1136/bmjopen-2020-039951. View

Guo J, Huang F, Liu J, Chen Y, Wang W, Cao B . The Serum Profile of Hypercytokinemia Factors Identified in H7N9-Infected Patients can Predict Fatal Outcomes. Sci Rep. 2015; 5:10942. PMC: 4450576. DOI: 10.1038/srep10942. View

Lu Q, Zhu Z, Tan C, Zhou H, Hu Y, Shen G . Changes of serum IL-10, IL-1β, IL-6, MCP-1, TNF-α, IP-10 and IL-4 in COVID-19 patients. Int J Clin Pract. 2021; 75(9):e14462. PMC: 8237069. DOI: 10.1111/ijcp.14462. View

Antonelli A, Ferrari S, Giuggioli D, Ferrannini E, Ferri C, Fallahi P . Chemokine (C-X-C motif) ligand (CXCL)10 in autoimmune diseases. Autoimmun Rev. 2013; 13(3):272-80. DOI: 10.1016/j.autrev.2013.10.010. View

Liu Y, Zhang C, Huang F, Yang Y, Wang F, Yuan J . Elevated plasma levels of selective cytokines in COVID-19 patients reflect viral load and lung injury. Natl Sci Rev. 2021; 7(6):1003-1011. PMC: 7107806. DOI: 10.1093/nsr/nwaa037. View

10.

Camon A, Alonso R, Munoz F, Cardozo C, Bernal-Maurandi J, Albiach L . C-reactive protein cut-off for early tocilizumab and dexamethasone prescription in hospitalized patients with COVID-19. Sci Rep. 2022; 12(1):5250. PMC: 8960074. DOI: 10.1038/s41598-022-08882-x. View

11.

Tamayo-Velasco A, Penarrubia-Ponce M, Javier Alvarez F, Gonzalo-Benito H, de la Fuente I, Martin-Fernandez M . Evaluation of Cytokines as Robust Diagnostic Biomarkers for COVID-19 Detection. J Pers Med. 2021; 11(7). PMC: 8303564. DOI: 10.3390/jpm11070681. View

12.

Guo J, Wang S, Xia H, Shi D, Chen Y, Zheng S . Cytokine Signature Associated With Disease Severity in COVID-19. Front Immunol. 2021; 12:681516. PMC: 8418386. DOI: 10.3389/fimmu.2021.681516. View

13.

Kwon J, Kim J, Kim M, Park S, Kim B, Bae S . Factors of Severity in Patients with COVID-19: Cytokine/Chemokine Concentrations, Viral Load, and Antibody Responses. Am J Trop Med Hyg. 2020; 103(6):2412-2418. PMC: 7695090. DOI: 10.4269/ajtmh.20-1110. View

14.

Can F, Ozkurt Z, Ozturk N, Sezen S . Effect of IL-6, IL-8/CXCL8, IP-10/CXCL 10 levels on the severity in COVID 19 infection. Int J Clin Pract. 2021; 75(12):e14970. PMC: 8646602. DOI: 10.1111/ijcp.14970. View

15.

Shankar-Hari M, Vale C, Godolphin P, Fisher D, Higgins J, Spiga F . Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19: A Meta-analysis. JAMA. 2021; 326(6):499-518. PMC: 8261689. DOI: 10.1001/jama.2021.11330. View

16.

Wang G, Gao H, Wang Y, Wei X, Liu Y, Lu J . Serum IP-10 and IL-7 levels are associated with disease severity of coronavirus disease 2019. Cytokine. 2021; 142:155500. PMC: 7973056. DOI: 10.1016/j.cyto.2021.155500. View

17.

Ruffilli I, Ferrari S, Colaci M, Ferri C, Fallahi P, Antonelli A . IP-10 in autoimmune thyroiditis. Horm Metab Res. 2014; 46(9):597-602. DOI: 10.1055/s-0034-1382053. View

18.

Gordon A, Mouncey P, Al-Beidh F, Rowan K, Nichol A, Arabi Y . Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19. N Engl J Med. 2021; 384(16):1491-1502. PMC: 7953461. DOI: 10.1056/NEJMoa2100433. View

19.

Dorward D, Russell C, Um I, Elshani M, Armstrong S, Penrice-Randal R . Tissue-Specific Immunopathology in Fatal COVID-19. Am J Respir Crit Care Med. 2020; 203(2):192-201. PMC: 7874430. DOI: 10.1164/rccm.202008-3265OC. View

20.

. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet. 2021; 397(10285):1637-1645. PMC: 8084355. DOI: 10.1016/S0140-6736(21)00676-0. View